Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Press release
View:
Post by fossi_2002 on Feb 23, 2024 9:54am

Press release

With this press release, Gilles is trying to get the last shareholders on his side or to gather the votes for the merger.

Comment by PBaelishh on Feb 23, 2024 10:56am
Yup - Gagnon is playing his classics. It has been revenue, revenue, revenue all along so he could hide what is really going on with VOLUME.  Now Gagnon releases ONE tidbit on volume!  On its it own, Symrise ordering volume of 20t is not that meaningful in the absence of context. Analysts see through this sheeit and that is why NOBODY follows Ceapro, a CEO who does not understand or ...more  
Comment by PBaelishh on Feb 23, 2024 11:05am
PS Ultimately with a 20t order in Q1, Gagnon thinks he can write-off how 2023 ended!!! Think about it... We have been begging for guidance with every quarterly release as he always waits until the last day possible to release results.  For example, Q4-23 was 2/3 over when he released results and, despite that, Gagnon offered no guidance on where 2023 would end up. NOW, he releases ...more  
Comment by lscfa on Feb 23, 2024 12:37pm
From the info circ. --- Ceapro’s dedicated production team successfully responded to the growing market demand for the cosmeceutical base business by producing over 300 metric tons of active ingredients in 2022.
Comment by lscfa on Feb 23, 2024 12:42pm
Gagnon thinks the NR shows many opportunities ahead for CZO. Long time shareholders see it as a lack of focus and execution in commercializing anything.
Comment by prophetoffactz on Feb 23, 2024 1:10pm
I see rare focus. Gilles is a visionary and on the cusp of disrupting major global markets. Right from the start a decade ago Gilles had a vision of building a base business with the two active ingredients and broadening the application of those two ingredients(beta glucan, avenanthramide) into new scientific claims. Dry powder formulations of beta glucan and avenanthramide have been developed ...more  
Comment by Hopeforthebest on Feb 23, 2024 2:51pm
Iscfa, In total agreement with your accessment of the news release. This has been the first news in years where the shareholders have been insight of the socall development of the Czo pipeline. IT HAS BEEN YEARS SINCE WE HAVE BEEN GIVEN UPDATES OF PRODUCT DEVELOPMENT AND STATUS.  Now just weeks before the proposed merger we are finally given a ducking update. Well to little and WAY TO ...more  
Comment by Ciao on Feb 25, 2024 8:06am
Unusual volume, highest in a year, was someone waiting for an update before jumping in, in a big way? Can we dream about a white knight or is someone positioning themself as a NO is coming?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities